Source link : https://www.newshealth.biz/health-news/cosibelimab-okd-for-cutaneous-squamous-cell-carcinoma/
The FDA approved cosibelimab (Unloxcyt) for treating metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) in adults who are not candidates for curative surgery or radiation. Approval of the new PD-L1 blocking antibody was based on results from CK-301-101, a multicenter, open-label, phase I trial that included 109 patients with metastatic (nodal and/or distant) […]
Author : News Health
Publish date : 2024-12-16 17:15:44
Copyright for syndicated content belongs to the linked Source.